Families and communities

PATH supported strong families and strong communities by expanding access to lifesaving vaccines, safe water, and malaria control strategies. Read about three of our most noteworthy 2011 accomplishments below.

Millions of young Africans protected against deadly meningitis

Innovation: MenAfriVac™ is a revolutionary new vaccine developed by PATH, the World Health Organization (WHO), and two dozen global collaborators. It protects against meningitis A, one of Africa’s most dreaded infectious diseases, which has ravaged the continent for more than a century.

Impact: In 2011, PATH, WHO, and our partners worked with the governments of Cameroon, Chad, and Nigeria to introduce MenAfriVac™. These countries joined Burkina Faso, Mali, and Niger in introducing the new vaccine at large scale. More than 54 million Africans between the ages of 1 and 29 have received the vaccine, with not a single case of group A meningococcal meningitis reported among those vaccinated. Innovation Funding

Bar graph showing number of Africans vaccinated with MenAfriVac™. 2010, 19.5 million; 2011, 35 million; 2016, 320 million.

A world without malaria

With elimination of malaria now within reach in Ethiopia, Senegal, and Zambia, PATH is partnering with national programs to pioneer new strategies to decrease malaria transmission and improve community health. In 2011, we helped train workers in nearly 400 clinics across 17 districts in Zambia in advanced surveillance methods. Some workers received additional training to find remaining cases at the community level and provide treatment to kill the parasite.

Safe water solutions

PATH and five private-sector collaborators developed new water filters and filter elements aimed at low-income consumers in developing countries to protect families from illnesses spread by contaminated water.

Learn more

MenAfriVac is a trademark of Serum Institute of India Ltd.